ARTICLE | Company News
LXR other research news
October 16, 1995 7:00 AM UTC
The Richmond, Calif., company received a $100,000 Phase I SBIR from the National Institute of Allergy and Infectious Diseases to study the role of Fas/CD95 in HIV infection. The antigen is a receptor molecule involved in the programmed cell death of immune system cells and other cell types. ...